Current status of tumour markers

References

• Schwartz M K. Specialized techniques of cancer management and diagnosis: Section 3: Cancer Markers. Cancer: Principles and Practice of Oncology.4th Edition, V DeVita, S Hellman, S. Rosenberg. J.B. Lippencott Company, Phil, Pa 1993; 531–541
   Google Scholar
• Schwartz M K. Laboratory Diagnosis for Cancer: A Look at the Future. Antibiotics and Chemotherapy., 22: 176–184
   PubMedGoogle Scholar
• Schwartz M K. Screening for Cancer: Is It Cost Effective?. Clin Chem 1993; 39: 2392–2403
   Google Scholar
• Birkmayer GJD, Schwartz M K, Klavins J V. Quality assurance of tumour markers assays. J Tumour Marker Oncol. 1990; 5: 195–202
   Google Scholar
• Nisselbaum J S, Bosl G J, Golbey R B, Schwartz D, Schwartz M K. Changes in serum α-fetoprotein and chorionic gonadotropin in response to cancer therapy. Annals Clin Lab Sci 1984; 14: 178–188
   Google Scholar
• Nisselbaum J S, Bosl G, Schwartz M K. Argument in favor of using mass units to calibrate and report concentrations of human choriogonadotropin. Clin Chem 1986; 32: 1998–2000
   PubMedGoogle Scholar
• Saller B, Clara R, Spottl G, Siddle K, Marin K. Testicular cancer secretes intact human choriogonadotropin (hCG) and its free β-subunit: Evidence that hCG (+hCG-(β) assays are the most reliable in diagnosis and follow-up. Clin Chem 1993; 36: 234–239
   Google Scholar
• Bosl G J, Geller N L, Cirrincione L, Vagelezang N J, Kennedy B J, Whitmore WF, Jr., Vugrin D, Scher H, Nisselbaum J, Golbey R B. Multivariate analysis of prognostic variables in patients with metastatic testicular cancer. Cancer Res 1983; 43: 3403–3407
   PubMed Web of Science ®Google Scholar
• Toner G C, Geller N L, Tan C, Nisselbaum J, Bosl G J. Serum tumour marker half-life during chemotherapy allows early prediction of complete response and survival in nonseminomatous germ cell tumours. Cancer Res 1990; 50: 5904–5910
   PubMed Web of Science ®Google Scholar
• Byrne D J. Brit J Surg 1990; 77: 1010–1013
   PubMed Web of Science ®Google Scholar
• Gail M H, Nuenz L, McIntire R, Radovich B, Braunstein G, Brown P R, Deftos L, Dnistrian A, Dunsmore M, Elashoff R, Geller N, Go VLW, Hirji K, Klauber M R, Pee O, Petroni G, Schwartz M, Wolfsen A R. Multiple markers for lung cancer diagnosis: validation of models for advanced lung cancer. J Natl Cancer Inst 1986; 76: 805–816
   PubMedGoogle Scholar
• Gail M H, Muenz L, McIntire K R, Radovich B, Braunstein G, Brown P R, Deftos L, Dnistrian A M, Dunsmore M, Elashoff R, Geller N, Go V L, Hirji K, Kaluber M R, Pee D, Petroni G, Schwartz M K, Wolfsen A R. Multiple markers for lung cancer diagnosis: valivation of models for localized lung cancer. J Natl Cancer Inst 1988; 80: 97–101
   PubMedGoogle Scholar
• Dnistrian A M, Greenberg E J, Smith C A, Schwartz D C, Schwartz M K. Evaluation of CAM26, CAM29, CA 15—3 and CEA as circulating tumour markers in breast cancer. Tumour Biol 1991; 12: 82–90
   PubMedGoogle Scholar
• Dnistrian A M, Schwartz M K, Greenberg E J, Smith C A, Schwartz D C. CA 15—3 and carcinoembryonic antigen in the clinical evaluation of breast cancer. Clin Chim Acta 1991; 200: 81–94
   PubMed Web of Science ®Google Scholar
• Dnistrian A M, Schwartz M K, Greenberg E J, Smith C A, Dorsa K, Schwartz D C. CA 549 as a marker in breast cancer. Int J. Biological Marker 1991; 6: 139–143
   PubMedGoogle Scholar
• Dnistrian A M, Schwartz M K, Schwartz D C, Nisselbaum J S. An evaluation of breast antigen BR 27.29 in serum of patients with breast cancer. Clin Chem 1993; 39: 1192
   Google Scholar
• Moertel C G, Fleming T R, Macdonald J S, Haller D G, Laurie J A, Tangen C. An evalntigen test (CEA) test for monitoring patients with resected colon cancer. J Am Med Assoc 1994; 270: 943–944
   Google Scholar
• Minton J P, Hoehn J L, Gerber D M, Hosley J S, Connelly D P, Salwan F, Fletcher W S, Cruz AB, Jr., Gatchell F G, Orieo M, et al. Results of a 400-patient carcinoembryonic antigen second look colorectal cancer study. Cancer 1985; 55: 1284–1290
   PubMed Web of Science ®Google Scholar
• Maehara Y, Sugimachi K, Akagi M, Kakegawa T, Shimaza H, Tomita M. Serum carcinoembryonic antigen level increases correlate with tumour progression in patients with differentiated gastric carcinoma following non curative resection. Cancer Res 1990; 50: 3952–3955
   PubMedGoogle Scholar
• Kiang D T, Greenberg L J, Kennedy B J. Tumour marker kinetics in the monitoring of breast cancer. Cancer 1990; 65: 193–199
   PubMedGoogle Scholar
• Price T, Beatty B G, Beatty J D, McNally A J. Human anti-murine antibody interference in measurement of carcinoembryonic antigen assessed with a double-antibody enzyme immunoassay. Clin Chem 1991; 37: 51–57
   PubMed Web of Science ®Google Scholar
• Parker L, Craft W W. Neuroblastoma screening; more questions than answers. Lancet 1991; 337: 344–346
   PubMedGoogle Scholar
• Heyward W L, Lamer A P, McMahon B J, Fitzgerald M A, Kilkenny S, Paprocki T R, et al. Early detection of primary hepatocellular carcinoma: screening for primary hepatocellular carcinoma among persons infected with hepatitis B virus. J Am Med Assoc 1990; 254: 3052–3054
   Google Scholar
• Zurawski VR, Jr., Orjasetec H, Anderson A, Jellum E. Elevated serum CA 125 levels prior to diagnosis of ovarian neoplasia relevance for early detection of ovarian cancer. Int J Cancer 1988; 42: 677–680
   PubMed Web of Science ®Google Scholar
• Daoud E, Bodar G, Weaver C, Ladenson J H, Scott M G. CA 125 concentrations in malignant andnonmalignant disease. Clin Chem 1991; 37: 1986–1974
   Google Scholar
• Carlson K J, Skates S J, Singer D E. Screening for ovarian cancer. Annals Inst Med 1994; 121: 127–132
   Google Scholar